Jianqiao Guo

Title: Jianqiao Guo: Innovator in Anti-Tumor Drug Development

Introduction

Jianqiao Guo is a prominent inventor based in Shijiazhuang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cyclin-dependent kinase 9 (CDK9). His work is crucial in the fight against hyperproliferative diseases, including various forms of cancer.

Latest Patents

Jianqiao Guo holds a patent for a compound as a cyclin-dependent kinase 9 inhibitor. This patent describes a compound represented by a specific formula, along with its pharmaceutically acceptable salts, stereoisomers, isotope derivatives, or prodrugs. The compound demonstrates excellent activity as a CDK9 inhibitor, showing promise in treating hyperproliferative diseases. Experimental research indicates that it effectively inhibits cell proliferation in vitro and suppresses tumors in vivo. The compound exhibits strong inhibitory effects on MV4;11 cells and in vivo tumor models, showcasing good selectivity, low toxicity, and minimal side effects. This positions it as a valuable candidate for novel anti-tumor drugs.

Career Highlights

Jianqiao Guo is affiliated with Cspc Zhongqi Pharmaceutical Technology Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential clinical value in oncology.

Collaborations

Jianqiao collaborates with notable colleagues, including Yongzhao Mu and Yan Zhang, who contribute to his research endeavors and the development of innovative pharmaceutical solutions.

Conclusion

Jianqiao Guo's contributions to the field of anti-tumor drug development highlight his role as an influential inventor. His patented compound represents a significant advancement in the treatment of hyperproliferative diseases, showcasing the potential for improved clinical outcomes.